As an alternative, targeting pathways downstream of HIF signaling includes the use of anti-VEGF therapy (monoclonal antibodies targeting VEGF (bevacizumab) or small molecule inhibitors targeting the VEGF receptor), which has been used for anti-angiogenic/vascular normalization effects in certain medical indications including ovarian, renal, lung or colorectal cancers, in combination with chemotherapy [171]. The gene discussed is VEGFA; the disease is colorectal cancer.